Radiopharmaceuticals in Development

  • 177Lu-PSMA

    After the 18F-PSMA-1007 exam, where metastatic lesions from prostate cancer are identified, the PSMA marked with 177 Lu, a β- emitting radionuclide, is ideal for use in radionuclide therapy directed at patients with metastatic prostate cancer. The radiopharmaceutical binds to cancer cells
    due to the high affinity of PSMA to its receptors present in these cells and the action of 177 Lu causes its destruction.


    Neuroendocrine tumors are considered rare, however, their incidence has increased in recent years, possibly due to the emergence of new and more sensitive techniques for their detection. They are usually found in the intestinal spent region and have an overexpression of somatostatin receptors on the cell surface. Somatostatin analogues such as octreotide (OCD) are widely used, together with a radioisotope, for the detection of these tumors. 18F-AlF-NOTATOC is a radiopharmaceutical capable of detecting these tumors and uses 18 F as a radioisotope, which has advantages over the radioisotopes most used today such as 68 Ga and 99m Tc.